Kairos Pharma (KAPA) announced positive safety results from its ongoing Phase 2 clinical trial of ENV-105 in patients with metastatic castration-resistant prostate cancer. The interim safety analysis of the first 10 enrolled patients demonstrated that ENV-105 was well tolerated when combined with standard-of-care hormone therapy, apalutamide. To date, no dose-limiting toxicities, unexpected adverse events, or Grade 3 or 4 toxicities were observed. Interim efficacy data from the trial are expected to be reported in September 2025.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KAPA: